Corcept Therapeutics Inc

6 de nov. de 2026, 20:52 UTC

Corcept Therapeutics shares are advancing after reporting a third-quarter net income of $126.78 million and diluted EPS of $1.01, despite earlier session pullbacks.

5 de nov. de 2026, 21:03 UTC

Selling pressure after 13.16k shares sold, lower sales guidance reaffirmed.

4 de nov. de 2026, 21:02 UTC

Corcept Therapeutics' Overweight rating was reaffirmed by Piper Sandler, which raised its price target to $173, despite disappointing revenue guidance for 2026.

3 de nov. de 2026, 23:01 UTC

Corcept Therapeutics reported Q3 revenue of $340.5 million and net income of $126.8 million, but reiterated full-year guidance of $1.1 billion to $1.2 billion.

2 de nov. de 2026, 21:09 UTC

Corcept Therapeutics shares are declining, continuing a trend of modest losses since Friday, as the broader market also experiences its fifth consecutive session of declines.

30 de out. de 2026, 20:02 UTC

Corcept Therapeutics shares are sharply lower, reversing a trend of higher daily closes observed in recent sessions.

28 de out. de 2026, 19:51 UTC

Corcept Therapeutics shares are declining, trading significantly below its 20-day moving average and near the lower end of its one-month range.

27 de out. de 2026, 19:36 UTC

Corcept Therapeutics shares are advancing, having regained ground after pulling back earlier in the session, with a slight cumulative return since Monday's close.

26 de out. de 2026, 23:21 UTC

Corcept Therapeutics Inc is trading lower in after-hours, remaining near the lower end of its one-month range and significantly below its 20-day moving average.

23 de out. de 2026, 23:51 UTC

Corcept Therapeutics Inc is rising in after-market trading, recovering from an earlier dip to its highest point of the day despite recent declines.

22 de out. de 2026, 20:02 UTC

Corcept Therapeutics Inc shares fell sharply, breaking from a recent trend of higher daily closes and indicating a downward shift in momentum.

20 de out. de 2026, 20:08 UTC

Corcept Therapeutics shares gained following a report recommending hypercortisolism screening in type 2 diabetes, citing positive results from its CATALYST study on mifepristone.

16 de out. de 2026, 20:01 UTC

Corcept Therapeutics Inc shares fell sharply, marking a notable decline and extending a streak of four consecutive sessions closing lower.

15 de out. de 2026, 20:02 UTC

Corcept Therapeutics Inc shares are declining, having reached their lowest point around mid-afternoon after an early peak earlier in the session.

14 de out. de 2026, 19:53 UTC

Corcept Therapeutics Inc shares fell sharply, continuing a downward trend since Tuesday's close, despite peaking in the late morning.

9 de out. de 2026, 19:55 UTC

Corcept Therapeutics Inc is trading higher, having gained notably since Thursday's close and currently positioned above its 20-day moving average.

7 de out. de 2026, 19:35 UTC

Corcept Therapeutics Inc is trading modestly higher, positioned significantly above its 20-day moving average and near the upper end of its one-month range.

6 de out. de 2026, 23:55 UTC

Corcept Therapeutics Inc is trading higher in after-market hours, remaining above its 20-day moving average following a significant U.S. trade deficit of $105.6 billion in August.

5 de out. de 2026, 20:01 UTC

Corcept Therapeutics Inc is trading sharply higher with unusually high share volume, nearing the upper end of its one-month trading range.

1 de out. de 2026, 20:08 UTC

Corcept Therapeutics Inc shares fell sharply, declining from Wednesday's close and reaching a low before slightly recovering, remaining in the middle of its one-month trading range.

30 de set. de 2026, 20:01 UTC

Corcept Therapeutics Inc is seeing higher trading activity with increased market volume and has gained ground since Tuesday, reaching a session high today.

29 de set. de 2026, 20:07 UTC

Corcept Therapeutics Inc shares fell, continuing a trend with four consecutive sessions down since Monday, despite an earlier brief rebound.

28 de set. de 2026, 19:34 UTC

Corcept Therapeutics Inc shares fell sharply amid a broader market downturn, coinciding with significant declines in major tech stocks and rising inflation concerns.

25 de set. de 2026, 19:15 UTC

Corcept Therapeutics Inc shares fell sharply after an early high, reflecting a notable decline amid mixed broader market signals and flat U.S. durable goods orders.

24 de set. de 2026, 23:06 UTC

Corcept Therapeutics Inc is trading lower during after-market hours, reflecting a broader market decline despite some recovery from earlier lows.

23 de set. de 2026, 20:04 UTC

Corcept Therapeutics shares fell following the announcement of Sean Maduck's retirement as President of Endocrinology, with Justin Gunn set to take over.

22 de set. de 2026, 19:34 UTC

Corcept Therapeutics' stock is advancing after the European drug regulator recommended approval for its cancer therapy, relacorilant, based on positive Phase 3 trial data.

21 de set. de 2026, 20:06 UTC

Corcept Therapeutics Inc is advancing, maintaining significant gains since Friday's close, despite earlier pulling back from a session high.

18 de set. de 2026, 20:02 UTC

Shares of Corcept Therapeutics fell sharply despite a positive CHMP opinion on relacorilant for ovarian cancer and a reiterated Buy rating from HC Wainwright.

17 de set. de 2026, 20:01 UTC

Corcept Therapeutics shares are rising, supported by record revenue and net income growth for Q2 2026, along with an increased revenue guidance of up to $1.2 billion.